Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (Pediatric MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica
Trial Phone: 321.841.5357 ; 321.841.2008 ; 321.841.3837
-
IRB No: APEC1621H
Protocol Abbrev: APEC1621H
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621H
Treatment: Drug: Olaparib
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03233204
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with olaparib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the deleterious genetic alterations in the DNA damage repair (DDR) pathway.
-
Key Eligibility
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
